![Won-Keun Kim]()
Won-Keun Kim1,2,3, MD, PhD; Moritz Seiffert4, MD, PhD; Andreas Rück5, MD, PhD; David M. Leistner6,7, MD, PhD; Henryk Dreger7,8, MD, PhD; Hendrik Wienemann9, MD; Matti Adam9, MD, PhD; Helge Möllmann10, MD, PhD; Johannes Blumenstein10,11, MD, PhD; Clemens Eckel10,11, MD; Andrea Buono12, MD; Diego Maffeo12, MD; Antonio Messina13, MD; Andreas Holzamer14, MD; Samuel Sossalla14, MD, PhD; Marco Barbanti15, MD; Giuliano Costa15, MD; Silvia Motta15, MD; Corrado Tamburino15, MD; Ina von der Heide4, MD; Julius Glasmacher7,8, MD; Mohammad Sherif7,8, MD, PhD; Philipp Seppelt6, MD; Stephan Fichtlscherer6, MD, PhD; Thomas Walther6, MD, PhD; Fausto Castriota16, MD; Roberto Nerla16, MD; Christian Frerker17, MD, PhD; Tobias Schmidt17, MD, PhD; Alexander Wolf18, MD; Martin M. Adamaszek18, MD; Francesco Giannini19, MD; Maarten Vanhaverbeke20, MD, PhD; Stefaan Van de Walle20, MD; Francis Stammen20, MD, PhD; Stefan Toggweiler21, MD, PhD; Stephanie Brunner21, MD; Antonio Mangieri22, MD; Mauro Gitto23, MD; Gerrit Kaleschke24, MD; Vlasis Ninios25, MD; Ilias Ninios25, MD; Judith Hübner26, MD; Erion Xhepa26, MD; Matthias Renker1,2, MD; Efstratios I. Charitos2; Michael Joner26, MD, PhD; Tobias Rheude26, MD, PhD
1. Kerckhoff Heart Center, Department of Cardiology, Bad Nauheim, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Rhein/Main, Germany; 2. Kerckhoff Heart Center, Department of Cardiac Surgery, Bad Nauheim, Germany; 3. Justus-Liebig University of Giessen, Department of Cardiology, Giessen, Germany; 4. University Heart and Vascular Center Hamburg, Department of Cardiology, University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Germany; 5. Karolinska University Hospital, Department of Cardiology, Stockholm, Sweden; 6. University Heart & Vascular Center Frankfurt, Frankfurt, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Rhein/Main, Germany; 7. Deutsches Herzzentrum der Charité (DHZC), Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany; 8. Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 9. Clinic III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; 10. Department of Cardiology, St. Johannes-Hospital, Dortmund, Germany; 11. Department of Cardiology, Carl-von-Ossietzky University, Oldenburg, Germany; 12. Interventional Cardiology Unit, Cardiovascular Department, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy; 13. Department of Cardiothoracic Surgery, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy in Operative Unit of Cardiac Surgery, Poliambulanza Foundation Ospital, Brescia, Italy; 14. University of Regensburg, Medical Center, Regensburg, Germany; 15. Division of Cardiology, AOU Policlinico G. Rodolico-San Marco, Catania, Italy; 16. Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy; 17. Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Department of Cardiology; Lübeck, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Germany ; 18. Contilia Herz- und Gefässzentrum, Elisabeth Krankenhaus Essen, Essen, Germany; 19. IRCCS Galeazzi Sant’Ambrogio, Milan, Italy ; 20. AZ Delta: Campus Rumbeke, campus Brugsesteenweg Roeselare, campus Menen en campus Torhout, Belgium; 21. Heart Center Lucerne, Lucerner Kantonsspital, Lucerne, Switzerland; 22. Cardiocenter, IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy; 23. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy; 24. Department of Cardiology III - Adult Congenital and Valvular Heart Disease University Hospital Muenster, Münster, Germany; 25. Interbalkan European Medical Center, Thessaloniki, Greece; 26. Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany
Disclaimer:
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention and
external reviewers - has been published immediately upon acceptance as it was received in the last round of
revision. The content of this article is the responsibility of the authors.
Please note that supplementary movies are not available online at this stage. Once a paper is published in
its edited and formatted form, it will be accompanied online by any supplementary movies.
To read the full content of this article, please log in to download the PDF.
Background: There is lack of comparative data on transcatheter aortic valve implantation (TAVI) in degenerated surgical prostheses (ViV).
Aims: We sought to compare outcomes of using two self-expanding transcatheter heart valve (THV) systems for ViV.
Methods: In this retrospective multicentre registry, we included consecutive patients undergoing transfemoral ViV using either the ACURATE neo/neo2 (ACURATE group) or EVOLUT R/PRO/PRO+ (EVOLUT group). The primary outcome measure was technical success (VARC-3). Secondary outcomes were 30-day all-cause mortality, device success (VARC-3), coronary obstruction (CO) requiring intervention, rates of severe prosthesis-patient mismatch (PPM), and aortic regurgitation (AR) ≥moderate. Comparisons were made after 1:1 propensity score matching.
Results: The study cohort comprised 835 patients from 20 centers (ACURATE n=251; EVOLUT n=584). In the matched cohort (n=468), technical success (ACURATE 92.7% vs. EVOLUT 88.9%; p=0.20) and device success (69.7% vs. 73.9%; p=0.36) as well as 30-day mortality (2.8% vs. 1.6%; p=0.392) were similar between the two groups. Mean gradients and rates of severe PPM, AR ≥moderate, and CO did not differ between the groups. Technical and device success were higher for the ACURATE platform among patients with true ID >19 mm, whereas a true ID ≤19 mm was associated with higher device success - but not technical success - among EVOLUT recipients.
Conclusion: ViV TAVI using either ACURATE or EVOLUT THVs showed similar procedural outcomes. However, a true ID >19 mm was associated with higher device success among ACURATE recipients, whereas in patients with true ID ≤19 mm device success was higher when using EVOLUT.
No account yet?
Sign up for free!
Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
from PCRonline.com
transcatheter aortic valve replacementvalve-in-valve procedureACURATEEVOLUTbioprosthesis
Read next article
Rotational atherectomy with cutting balloon to optimize stent expansion in calcified lesions: The ROTACUT randomized trial